Chimerix Stock News

Chimerix (NASDAQ:CMRX) had its target price decreased by Wedbush from $15.00 to $14.00 in a research report report published on Monday, Analyst Price Targets reports. Wedbush currently has an outperform rating on the biopharmaceutical companys stock. Several other brokerages have also commented on CMRX. HC Wainwright raised their price target on shares of Chimerix from []

Chimerix (NASDAQ:CMRX) had its target price increased by HC Wainwright from $19.00 to $21.00 in a research note published on Monday morning, The Fly reports. The firm currently has a buy rating on the biopharmaceutical companys stock. Other equities research analysts have also recently issued research reports about the stock. Maxim Group restated a buy []

– Plenary Session Presentation on Saturday, November 20 –

Plenary Session Presentation on Saturday, November 20

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

JPMorgan Chase & Co. increased its stake in Chimerix, Inc. (NASDAQ:CMRX) by 26.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,240 shares of the biopharmaceutical companys stock after purchasing an additional 5,926 shares during the period. JPMorgan Chase & Co.s holdings []

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q3 2021 Results - Earnings Call Transcript

Chimerix Inc (NASDAQ: CMRX) has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma (a most common type of brain cancer).  ONC201 is an orally

Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and -72.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends the

DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, t

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2021 Results - Earnings Call Transcript

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, to